在实体器官移植接受者中侵袭性菌感染的药理管理
Mario Fernández-Ruiz1,2,3
1Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
Expert opinion on pharmacotherapy
|March 4, 2024
概括
固体器官移植接受者容易受到侵入性真菌感染,如阿斯伯吉洛症和粘膜菌病. 审查了当前的治疗方法,强调了管理这些严重的移植后感染的挑战和未来方向.
科学领域:
- 菌类学 菌类学是指菌类学.
- 移植医学 移植医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 固体器官移植 (SOT) 接受者对入侵性真菌感染 (IFI) 的易感性增加,特别是丝状真菌.
- 移植后的侵入性阿斯伯吉洛症 (IA) 和粘菌菌病与高死亡率和移植损失有关.
- 在SOT接收者中管理这些IFI带来了独特的临床挑战.
研究的目的:
- 在SOT接受者中批判性地审查IA和粘膜菌病的当前治疗建议.
- 讨论特定的挑战,包括药物相互作用和治疗毒性.
- 探索移植后IFI药理管理的未来方向.
主要方法:
- 审查当前的治疗指导方针和支持证据的IA和粘膜菌在SOT接受者.
- 讨论抗真菌药物 (如三醇) 和免疫抑制剂之间的药物相互作用.
- 考虑免疫调节疗法和氨酸抑制剂的作用.
主要成果:
- 与voriconazole相比,像isavuconazole这样的进步提供了更好的耐受性和更少的药物相互作用.
- 在诸如组合疗法和免疫抑制降低策略等领域存在显著的改进空间.
- 新的抗真菌剂的确切作用需要进一步定义.
结论:
- 尽管取得了进展,但在SOT接收者中管理模具IFI仍然具有挑战性.
- 优化治疗策略,包括组合疗法和免疫抑制管理至关重要.
- 未来的研究应该专注于新型抗真菌剂及其具体贡献.
相关概念视频
01:24Tissue Transplantation
366
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
366
01:24Cystic Fibrosis: Management
164
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
164
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:29Pulmonary Tuberculosis I
242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
01:28Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324